Education
About Us
Working with TipRanks
Follow Us
TScan Therapeutics (TCRX)
NASDAQ:TCRX
Total Valuation
TScan Therapeutics has a market cap or net worth of $60.32M. The enterprise value is $2.05M.
Market Cap$60.32M
Enterprise Value$2.05M
Share Statistics
TScan Therapeutics has 52,625,034 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding52,625,034
Owned by Insiders20.28%
Owned by Institutions35.28%
Financial Efficiency
TScan Therapeutics’s return on equity (ROE) is -1.05 and return on invested capital (ROIC) is -62.51%.
Return on Equity (ROE)-1.05
Return on Assets (ROA)-0.57
Return on Invested Capital (ROIC)-62.51%
Return on Capital Employed (ROCE)-0.65
Revenue Per Employee51.63K
Profits Per Employee-648.83K
Employee Count200
Asset Turnover0.05
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of TScan Therapeutics is ―. TScan Therapeutics’s PEG ratio is 0.08.
PE Ratio―
PS Ratio12.58
PB Ratio1.05
Price to Fair Value1.05
Price to FCF-0.93
Price to Operating Cash Flow-1.02
PEG Ratio0.08
Income Statement
In the last 12 months, TScan Therapeutics had revenue of 10.32M and earned -129.77M in profits. Earnings per share was -1.00.
Revenue10.32M
Gross Profit7.46M
Operating Income-135.81M
Pretax Income-129.77M
Net Income-129.77M
EBITDA-132.95M
Earnings Per Share (EPS)-1.00
Cash Flow
In the last 12 months, operating cash flow was -135.32M and capital expenditures -4.41M, giving a free cash flow of -139.73M billion.
Operating Cash Flow-135.32M
Free Cash Flow-139.73M
Free Cash Flow per Share-2.66
Dividends & Yields
TScan Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.98
52-Week Price Change-31.61%
50-Day Moving Average1.08
200-Day Moving Average1.47
Relative Strength Index (RSI)47.83
Average Volume (3m)476.93K
Important Dates
TScan Therapeutics upcoming earnings date is May 12, 2026, Before Open (Confirmed).
Last Earnings DateMar 4, 2026
Next Earnings DateMay 12, 2026
Ex-Dividend Date―
Financial Position
TScan Therapeutics as a current ratio of 8.15, with Debt / Equity ratio of 76.46%
Current Ratio8.15
Quick Ratio8.15
Debt to Market Cap0.31
Net Debt to EBITDA0.44
Interest Coverage Ratio-49.05
Taxes
In the past 12 months, TScan Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
TScan Therapeutics EV to EBITDA ratio is -0.54, with an EV/FCF ratio of -0.51.
EV to Sales6.93
EV to EBITDA-0.54
EV to Free Cash Flow-0.51
EV to Operating Cash Flow-0.53
Balance Sheet
TScan Therapeutics has $152.41M in cash and marketable securities with $94.14M in debt, giving a net cash position of $58.27M billion.
Cash & Marketable Securities$152.41M
Total Debt$94.14M
Net Cash$58.27M
Net Cash Per Share$1.11
Tangible Book Value Per Share$0.95
Margins
Gross margin is 85.57%, with operating margin of -1315.38%, and net profit margin of -1256.81%.
Gross Margin85.57%
Operating Margin-1315.38%
Pretax Margin-1256.81%
Net Profit Margin-1256.81%
EBITDA Margin-1287.62%
EBIT Margin-1315.38%
Analyst Forecast
The average price target for TScan Therapeutics is $6.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$6.00
Price Target Upside466.04% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-10.03%
EPS Growth Forecast11.06%